Troglitazone from Cayman Chemical

A selective agonist of PPARγ (EC50s = 0.78 and 0.55 µM for the mouse and human receptors, respectively, in a transactivation assay); selective for PPARγ over PPARα and PPARδ, at which it is inactive at ≤10 µM; exhibits antihyperglycemic and antihyperlipidemic properties in Zucker diabetic fatty rats, reducing plasma glucose and triglyceride levels by 61 and 87% respectively, at 500 mg/kg twice per day; induces cell cycle arrest at the G1 phase in SK-HEP-1 and Hep3B hepatocellular carcinoma cells at 10 µM and increases apoptosis in these cells at ≥30 µM